



ORAGENICS

Oragenics, Inc. Engages GSP Consulting Corporation To Represent Its Breakthrough Scientific Research To The Government

Leading Consultancy Organization To Introduce Oragenics' Technologies For Government Programs

For Immediate Release

Tampa, FL (January 20, 2010) – **Oragenics, Inc.** (OTCBB: ORNI www.oragenics.com) has engaged government relations firm, GSP Consulting ("GSP"), to represent the Company for the purpose of securing government funding for a number of its technologies. GSP will focus on three areas where Oragenics has developed potentially breakthrough technologies.

First, deaths caused by infections continue to rise at alarming rates. The medical community has made it a top priority to identify and develop new classes of antibiotics that will combat infections that have become resistant to current antibiotics, as well as antibiotics to combat threats posed by bioterrorism. Oragenics' DPOLT synthetic chemistry platform allows the Company to synthesize MU 1140 and other antibiotics, which have the potential to address these pressing needs. Partnering with government and NGO healthcare organizations can increase the speed to market for antibiotics produced by this innovative platform.

Second, early detection of a disease is often critical to its successful treatment. Oragenics' PCMAT platform allows us to achieve this goal quickly and with great sensitivity by identifying novel diagnostic 'biomarkers' in the blood or urine of patients. With assistance from government funding, Oragenics can apply this new technology to a wide variety of diseases, including cancers, infections, traumatic injuries and autoimmune diseases.

Finally, Oragenics has also committed itself to developing solutions to the burgeoning increase in tooth decay, a chronic infectious disease that affect billions of people worldwide. The Company's SMaRT replacement therapy technology is simply swabbed onto the surfaces of the teeth once over a five minute period, and will then protect the patient against the bacterium that causes most tooth decay.

With assistance from government funding, Orogenics can complete the work into these new technologies that are anticipated to have a profound impact on improving the health of people in our country and throughout the world.

David Hirsch, the Company's President and CEO stated, "We are pleased to be working with GSP in our efforts to uncover non-dilutive governmental financing to advance our various technologies, especially MU1140, our lead antibiotic, and the DPOLT synthetic chemistry platform." Aaron Grau, a Partner with GSP and leader of its Federal Government Affairs Practice stated, "We are excited by Orogenics' technologies and we look forward to helping the company in its initiative to obtain governmental funding."

About Orogenics, Inc.

Orogenics, Inc. is a biopharmaceutical company engaged in developing unique proprietary technologies, some of which are being commercialized and sold in the over-the-counter consumer healthcare market. The Company also has a number of technologies in discovery, preclinical and clinical development, with a concentration in the main therapeutic area of infectious diseases, diagnostics, and oral health. The Company has offices located in Progress Corporate Park at 13700 Progress Boulevard in Alachua, Florida, approximately 15 miles from the campus of the University of Florida in Gainesville, and at 3000 Bayport Drive, suite 685 in Tampa, Florida.

About GSP Consulting

GSP's Federal Government Affairs practice has a national scope. The firm works with clients and congressional delegations from all 50 states. Their offerings include public policy advocacy ranging from energy and defense issues to health care, education and workforce development. GSP's federal government affairs professionals also have proven success in securing federal investments through legislative appropriations, competitive grants and administrative procurements.

###

Safe Harbor Statement: *Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect the Company's current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those set forth in our most recently filed annual report on Form 10-KSB and quarterly report on Form 10-Q, and other factors detailed from time to time in filings with the U.S. Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.*

CONTACT:

SSA Public Relations

(818) 907-5929

Steve Syatt

ssyatt@ssapr.com

Cara Downs

cdowns@ssapr.com

Oragenics, Inc.

(813) 286-7900

David Hirsch, President and CEO

dhirsch@oragenics.com